Bicycle Therapeutics (BCYC) AI Stock Analysis

• Market Cap: $559.30M
• Dividend Yield: N/A
• Average Volume (3M): 298.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -23.43%
• EPS Growth: -9.84%
• Country: US
• Employees: 305
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 49,929,950
• 10 Day Avg. Volume: 248,825
• 30 Day Avg. Volume: 298,522
• PEG Ratio: 0.11
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 23.10
• P/FCF Ratio: -4.91
• Enterprise Value/Market Cap: -0.19
• Enterprise Value/Revenue: -3.72
• Enterprise Value/Gross Profit: 2.67
• Enterprise Value/Ebitda: 0.38
• 1Y Price Target: $22.50
• Price Target Upside: 178.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 45 Neutral
• Price Target: $7.00 ▼(-13.26% Downside)

Bicycle Therapeutics faces significant financial and valuation challenges, with declining revenues and persistent losses being the most impactful factors. The technical analysis suggests a bearish trend, though there is potential for a rebound if market momentum improves. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Proprietary Technology

The proprietary Bicycle platform positions the company to develop innovative therapies, potentially leading to unique treatment options and competitive advantages in the biotechnology sector.

Low Leverage

A low leverage position provides financial flexibility, reducing risk and allowing the company to invest in R&D without the burden of high debt costs.

Strategic Partnerships

Collaborations with larger pharmaceutical companies can provide steady revenue streams, funding for R&D, and access to broader markets, enhancing long-term growth prospects.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in market penetration and product adoption, which could hinder long-term financial stability and growth.

Persistent Losses

Ongoing losses reflect operational inefficiencies and high costs, which could strain resources and limit the company's ability to invest in future growth opportunities.

Cash Flow Challenges

Cash flow difficulties can impact the company's ability to fund operations and R&D, potentially affecting its capacity to sustain long-term innovation and competitiveness.

Bicycle Therapeutics Business Overview & Revenue Model

Company Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

How the Company Makes Money

Bicycle Therapeutics generates revenue through a combination of product development partnerships, licensing agreements, and potential milestone payments from collaborations with larger pharmaceutical companies. The company collaborates with industry partners to develop its product candidates, which can lead to upfront payments, research funding, and milestone payments as the products progress through clinical development. Additionally, Bicycle may receive royalties on sales of any products that result from these partnerships. The company also aims to capitalize on its proprietary technology to attract investments and grants that can further support its research and development efforts.

Bicycle Therapeutics Financial Statement Overview

Summary

Bicycle Therapeutics faces significant financial challenges with declining revenues and persistent losses. The company maintains a low leverage position, which is a positive aspect, but the negative returns on equity and cash flow difficulties highlight operational inefficiencies. The biotechnology industry often involves high R&D costs, which may contribute to these financial pressures. Overall, the company needs to improve revenue generation and cost management to enhance financial stability.

Income Statement

Bicycle Therapeutics shows declining revenue with a negative growth rate of -25.07% in the TTM, indicating significant challenges in revenue generation. The company has consistently negative profit margins, with a TTM net profit margin of -12.57%, reflecting ongoing losses. The EBIT and EBITDA margins are also deeply negative, suggesting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.011 in the TTM, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative at -31.96%, highlighting poor returns for shareholders due to persistent losses. The equity ratio is relatively stable, suggesting a solid asset base funded by equity.

Cash Flow

Bicycle Therapeutics has a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth at 15.43% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally better than net income, but still negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.34M	35.27M	26.98M	14.46M	11.70M	10.39M
Gross Profit	-39.47M	-137.69M	-129.52M	-67.15M	-33.18M	-22.76M
EBITDA	-279.15M	-164.89M	-183.40M	-112.96M	-64.08M	-50.68M
Net Income	-250.66M	-169.03M	-180.66M	-112.72M	-66.82M	-51.01M
Balance Sheet
Total Assets	763.95M	956.87M	595.34M	410.61M	479.79M	161.15M
Cash, Cash Equivalents and Short-Term Investments	648.33M	879.52M	526.42M	339.15M	438.68M	135.99M
Total Debt	981.00K	9.49M	44.96M	44.33M	44.34M	15.78M
Total Liabilities	145.47M	163.81M	224.41M	139.83M	133.54M	65.69M
Stockholders Equity	618.48M	793.06M	370.93M	270.78M	346.25M	95.46M
Cash Flow
Free Cash Flow	-241.87M	-165.96M	-63.56M	-105.10M	-16.82M	-18.99M
Operating Cash Flow	-239.69M	-164.72M	-60.63M	-86.11M	-14.79M	-17.79M
Investing Cash Flow	-2.14M	-1.24M	-2.93M	-18.99M	-2.03M	-1.20M
Financing Cash Flow	87.00K	519.75M	250.03M	6.69M	320.73M	62.84M

Bicycle Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Negative. The current price of 8.07 is below the 20-day moving average (MA) of 8.17, above the 50-day MA of 7.66, and below the 200-day MA of 8.68, indicating a bearish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 35.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCYC.

Bicycle Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	―	$481.64M	-116.70	-22.06%	―	85.40%	40.95%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCAX	―	$887.45M	―	-32.71%	―	―	―
BCYC	―	$559.30M	―	-34.63%	―	-23.43%	-9.84%
NBTX	―	$988.89M	―	―	―	―	―
OPT	―	$480.87M	-3.01	―	―	-80.09%	60.14%
KOD	―	$957.39M	―	-140.33%	―	―	-0.69%

Bicycle Therapeutics Corporate Events

Bicycle Therapeutics Reports Q3 2025 Financial Results

Bicycle Therapeutics is a clinical-stage pharmaceutical company based in the United Kingdom, specializing in the development of a novel class of medicines known as Bicycle molecules, primarily targeting oncology indications with high unmet medical needs. The company is known for its unique therapeutic modality that combines the pharmacology of biologics with the manufacturing and pharmacokinetic properties of small molecules.

Bicycle Therapeutics Expands Board with New Appointments

On September 8, 2025, Bicycle Therapeutics announced the expansion of its Board of Directors from eight to ten members, appointing Roger Dansey, M.D., and Hervé Hoppenot as new directors. Both appointees bring extensive expertise in oncology research, drug development, and commercialization, which is expected to enhance the company’s strategic initiatives in developing next-generation targeted therapies. The appointments are seen as a strategic move to strengthen the company’s leadership as it progresses with its pipeline and anticipates upcoming milestones.

The most recent analyst rating on (BCYC) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.

Bicycle Therapeutics Reports Q2 2025 Financial Results

Bicycle Therapeutics is a clinical-stage pharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules, which are designed to address diseases underserved by existing therapeutics. The company operates in the biotechnology sector and is known for its proprietary bicyclic peptide technology.

Bicycle Therapeutics Appoints Charles Swanton to Board

On August 6, 2025, Bicycle Therapeutics announced the appointment of Charles Swanton, M.D., Ph.D., to its Board of Directors and Scientific Committee, effective August 12, 2025. This appointment is part of the company’s efforts to strengthen its clinical leadership and scientific advisory capabilities. Additionally, Bicycle Therapeutics reported its second-quarter 2025 financial results, highlighting significant progress in its research and development pipeline, including ongoing trials for zelenectide pevedotin in various cancers. The company also announced a strategic cost realignment, primarily through workforce reduction, to extend its financial runway into 2028, while continuing to focus on disciplined capital allocation and operational flexibility.

The most recent analyst rating on (BCYC) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.